Retrospective Analysis of Goal Assessment for Conservative Treatment and Surgical Intervention for Spasticity of Upper and Lower Limbs in an Interdisciplinary Neuro-Orthopedic Spasticity Clinic

Mézier J*, Zambelli PY, Bonnard Ch, Raffoul W, Vuadens Ph and Diserens K

Department of Orthopaedics and Traumatology Service, University of Lausanne, Switzerland.

*Corresponding author: Mézier J, Department of Orthopaedics and Traumatology Service, University of Lausanne, Switzerland. Tel: 41213149403; E-mail: julien.mezier@unil.ch

Received date: April 3, 2016; Accepted date: May 23, 2016; Published date: May 27, 2016

Copyright: © 2016 Mezier J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background and Objective: This retrospective study analyses the goal assessment of the treatment of spasticity. The outcome was to compare the efficiency of treatments in term of goal from the International Classification of Functioning, Disability and Health (ICF).

Methods: A database was created from the patients’ medical files. The efficiency of treatment was then evaluated using the improvement in the sub-goals of the ICF: pain (B280-B289), function of the joints and bones (B710-B729), improvement of mobility (D450-DN83) and personal maintenance (D510-D599). The results are discussed after a literature review.

Results: The botulinum toxin injection was more common than orthopedic procedures. Orthopedic procedures showed a tendency to be more efficient regarding the improvement in ICF objectives.

Conclusions: This study was unable to prove a statistically significant difference between botulinum toxin and orthopedic procedure regarding ICF objectives due to the number of subjects being too small. But it showed that 83.4% of patients were treated by botulinum toxin before surgery and only operated in the case of failed goal-achievement. The surgery then enabled the goal to be achieved. This systematic goal assessment is necessary in order to understand better the efficiency of the management of spasticity treatment methods.

Keywords: Spasticity; Management; Botulinum toxin; Orthopedic procedure

Introduction

Spasticity refers to an abnormal, velocity-dependent increase in muscle tone resulting from interruption of the neural circuitry regulating the muscle and is a common complication of cerebral palsy, brain injuries, spinal cord injuries, multiple sclerosis and stroke [1]. Its incidence after a stroke is 17% to 38% [2,3]. Moreover, the severity of spasticity increases over time [4] and induces significant pain, contractures, joint subluxations or dislocations, peripheral neuropathy and pressure ulcers [5].

The prevention of complications due to spasticity is therefore important to improve the quality of life of patients.

Among the different treatments of spasticity, botulinum toxin A is a well-tolerated and effective focal intervention for the reduction of spasticity, and it is widely recommended in clinical practice [6]. Botulinum toxin is only reimbursed by Swiss health insurance for spasticity due to a stroke and the maximal recommended dose per session in Switzerland is 400 IU. In some cases, repeated administration of botulinum toxin leads to the development of resistance due to circulating antibodies [7]. If the botulinum toxin treatment hadn’t a sufficient effect, it is possible to propose an orthopedic surgical approach to the patient.

Orthopedic procedures can be classified into three major categories: tenotomy, tendon transfer and tendon lengthening [8]. Tenotomies are reserved for the release of the tendon to severely spastic muscles [8]. Tendon lengthening is performed to weaken spastic muscles and position joints at a more natural and useful angle [8]. Tendon transfers are undertaken so that muscles, which remain at least partially functional, can produce useful movements [8]. Tendon lengthening and tendon transfer are most successful in the lower extremity and tend to improve borderline ambulation [9].

The management of spasticity needs a multidisciplinary approach to define treatment goals according to the International Classification of Functioning, Disability and Health (ICF). The assessment of the patient occurs over multiple visits to determine the correct combination of therapies and procedures to achieve the best function [10].

To fulfill this requirement a spasticity outpatient clinic has been developed in the Clinique Romande de Réadaptation and in the department of Neurology at the Lausanne University Hospital (CHUV). Both centers use the same scales and scores to evaluate patients. A first consultation evaluates the indication for a botulinum toxin treatment. When conventional treatments such as physiotherapy, occupational therapy, antispastic drugs or orthosis are insufficient to obtain a satisfactory improvement there is a neuro-orthopedic consultation. A surgical approach is discussed in the presence of an
orthopedic surgeon and a specialist in reconstructive and plastic surgery.

Patients and Methods

Patients

Inclusion criteria were to be older than 18, to suffer from spasticity and to have been evaluated in the interdisciplinary neuro-orthopedic spasticity clinic between December 2003 and November 2013. The spasticity should be severe enough to have an impact on the life of the patient. The only exclusion criterion was to have insufficient information in the medical records to complete the database.

Method

As the number of patients was too small to be statistically significant it was decided to carry out an observational study of a group of patients and the treatment they received for individual goal assessment. The goal assessments were taken from the main component of the International Classification of Functioning, Disability and Health (ICF). The database was created using data from patients’ medical files of the CHUV in Lausanne, the Neurological Centre Plein Soleil in Lausanne and the Reeducation Centre in Sion.

The primary outcome was to compare the efficiency of treatments in terms of ICF goals. For the chapter Body Function and Structure the chosen sub-goals for this study were improvement in function of the joints and bones (B710-B729) and decrease of pain (B280-B289). The mobility of joints was measured and compared before and after treatment. If the improvement was judged sufficient for the patient, the efficiency of treatment was considered as good efficiency. Because patients were followed for many years, it happened that a treatment with a good efficiency when the patient was first treated did not work well after a certain period. So to distinguish these from treatments which maintained good efficiency, they were noted as partially efficient.

The objective concerning pain was evaluated by the patient as good if the pain was relieved, partial if the treatment had no effect and bad if the treatment made the pain worse. The second ICF goal assessment corresponds to two sub-goals from activity and participation: mobility and self-care. Mobility is affected by spasticity in the lower limb(s) and self-care mostly concerns hand spasticity. So it was interesting to compare both. The improvement of mobility is important for patients with lower limb spasticity because it limits mobility and reduces quality of life [11]. Just as lower limb spasticity affects quality of life, upper limb spasticity can have a significant effect on self-care, like Toileting (D530) or Washing oneself (D510) [12]. Efficiency in terms of self-care and mobility were measured in the same way as the pain sub-goal: good for an improvement, partial if no improvement and bad if the situation got worse.

The secondary outcome was to compare the previous results with results from other articles.

Results

In total, 102 patients attended the interdisciplinary clinic from 2003 but 61 did not have sufficient information in their medical records. 47.6% of patients suffered from spasticity post-stroke. Of 41 patients retained for the study, 78% had botulinum toxin treatment and 44% had surgical treatment (Figure 1). None of our patients suffered from a sever complication of these treatments. Only a few patients had surgical treatment without first receiving botulinum toxin (7.3%). Regarding the indication for treatment, we were able to group patients according to four ICF goals: lowering pain (B280-B289), increasing function of the joints and bones (B710-B729), increasing walking performance (D450-N83) and improving personal maintenance (D510-D599) (Figure 2).

The efficiency of decreasing pain was good except for 14% who had partial efficiency. The efficiency of increasing function of the joints and bones was 45% good efficiency, 45% partially efficient and 10% bad efficiency (Figure 3). Botulinum toxin injections accounted for 84% of the treatments improving function.

In the improvement of walking, 31% of the patients had only botulinum toxin injection, 13% only surgery and 54% had toxin...
botulinum injections followed by surgery. For surgery the major indication for treatment was spastic equinovarus foot: the efficiency was good for 73% of the patients and partial for 27%. Botox had a good efficiency in 31%, partial efficiency in 57%, and bad efficiency in 10% (Figure 3). Regarding an improvement in personal maintenance, 44% of patients had surgical treatment. The surgery efficiency was good in 50% and partial in 50%. For the botox, there was 20% of good improvement, 60% partial and 20% bad (Figure 3).

**Discussion**

The botulinum toxin injection treatment was the procedure patients in this study had the most. It can be explained by the fact that botulinum toxin is a safe and reversible procedure. Indeed, effects will last a few months and if the treatment is not satisfying, another procedure can still be tried. In our study, the high number of patients treated with botulinum toxin can also be explained by the type of study. Indeed, as a retrospective observational study, no randomization had been done and the all our patients first went to a spasticity clinic to evaluate the indication of a botulinum toxin injection. In the literature, many articles can be found to prove the efficiency and safety of botulinum toxin. For example, a retrospective analysis from Baricich A et al. [13] evaluated the efficacy and safety of high doses of botulinum toxin in 26 patients affected by upper and/or lower limb post-stroke spasticity. No adverse events were reported and high doses of botulinum toxin were shown to be effective and safe.

The results of the study show that a minority of patients had surgical treatment but with a better improvement in ICF objectives (Figure 4). There is a selection bias, because as surgery does not allow an easy way back, the surgeon will recommend surgery only for patients who he is sure will benefit from it. But, even so, we found a study from Van Heest et al. [14] which compared botulinum toxin injection treatment, surgical treatment and ongoing treatment for children with upper-extremity cerebral palsy. They demonstrated that surgical treatment provides a greater improvement, of modest magnitude, than botulinum toxin injections or regular, ongoing therapy at twelve months.

Regarding the patients' activity, an improvement in walking was demonstrated by a lot of patients with varus equinus spastic foot deformity who had surgical treatment. A retrospective study from Vogt et al. [15] confirms that surgery for equinovarus foot can increase the walking distance. Of 82 patients who were examined up to 65 months after surgery, 74 reported an increase in their walking distance even if moderate. But we also found a study which confirms the efficiency of botulinum toxin injection for equinus foot [16]. So a good multidisciplinary evaluation should be carried out to find the better management depending on the situation.
To compare improvement in mobility which is affected by lower limb spasticity and improvement in personal maintenance which is affected by upper limb spasticity, treatments provided better improvement in walking than in personal maintenance [17]. Maybe the management of lower limb spasticity is better than upper limb spasticity, but with such a small number of patients, the difference is probably not significant. This would be an interesting subject to study in a future research project.

Conclusion

This retrospective observational study shows that a minority of patients had surgical treatment but with better improvement in ICF objectives. But as it is a safer procedure, with 60% of partial success we recommend always trying the botox treatment before surgery. Further studies with goal assessment are needed with a larger population and prospective goal assessment based on ICF evaluation should be completed considering the individual needs of the patient, taking account of the heterogeneous context.

Declaration of interest

There were no financial or personal relationships with other people or organizations that could inappropriately influence this article.

References

1. Satkunam LE (2003) Rehabilitation medicine: 3. Management of adult spasticity. CMAJ 169: 1173-1179.
2. Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK, et al. (2004) Predicting spasticity after stroke in those surviving to 12 months. Clin Rehabil 18: 438-443.
3. Lundström E, Terént A, Borg J (2008) Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 15: 533-539.
4. Opheim A, Danielsen A, Alt Murphy M, Persson HC, Sunnerhagen KS (2014) Upper-limb spasticity during the first year after stroke: stroke arm longitudinal study at the University of Gothenburg. Am J Phys Med Rehabil 93: 884-896.
5. Gorgey AS, Chiádo AE, Gater DR (2010) Oral baclofen administration in persons with chronic spinal cord injury does not prevent the protective effects of spasticity on body composition and glucose homeostasis. Spinal Cord 48: 160-165.
6. Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P, Zakine B (2013) Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. BMJ Open 3: e002230.
7. Brin MF (1997) Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. See comment in PubMed Commons below Muscle Nerve Suppl 6: S146-168.
8. Jóźefczyk PB (2002) The management of focal spasticity. See comment in PubMed Commons below Clin Neuropharmacol 25: 158-173.
9. Bleck EE (1975) Locomotor prognosis in cerebral palsy. See comment in PubMed Commons below Dev Med Child Neurol 17: 18-25.
10. De Roode CP, James MA, Van Heest AE (2010) Tendon transfers and releases for the forearm, wrist, and hand in spastic hemiplegic cerebral palsy. Tech Hand Up Extrem Surg 14: 129-134.
11. Martin A, Abogunrin S, Kurth H, Dinet J (2014). Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat 10:1 11-122.
12. World Health Organisation (2001) International Classification of Functioning, Disability and Health (ICF).
13. Baricich A, Graña E, Carda S, Santamato A, Cisari C, et al. (2015) High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis. J Neural Transm (Vienna) 122: 1283-1286.
14. Van Heest AE, Bagley A, Molitor F, James MA (2015) Tendon transfer surgery in upper-extremity cerebral palsy is more effective than botulinum toxin injections or regular, ongoing therapy. J Bone Joint Surg Am 97: 529-536.
15. Vogt JC, Bach G, Cantini B, Perrin S (2011) Split anterior tibial tendon transfer for varus equinus spastic foot deformity Initial clinical findings correlate with functional results: A series of 132 operated feet. Foot Ankle Surg 17: 178-181.
16. Cardoso ES, Rodrigues BM, Barroso M, Menezes CJ, Lucena RS, et al. (2006) Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. See comment in PubMed Commons below Pediatr Neuro 34: 106-109.
17. Simpson DM, Gracies JM, Graham K, Hallett M, Miyasaki J, et al. (2009). Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 73: 736-737.